MacroGenics Inc - Company Profile
Powered by 
All the sales intelligence you need on MacroGenics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how MacroGenics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with MacroGenics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
MacroGenics Inc (MacroGenics) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for cancer treatment. The company's main activities include the discovery and development of antibody-drug conjugates and multi-specific antibodies, such as DART and TRIDENT molecules. The company’s products pipeline include investigational drugs like lorigerlimab, MGC026, and MGC028. MacroGenics' products are primarily aimed at patients with various types of cancer, including hematological malignancies and solid tumors. The company offers other products through partnered programs to treat HER2 and metastatic breast cancer, T1D, Heme Malignancies, carcinoma, lung cancer, and multiple solid tumors. MacroGenics is headquartered in Rockville, Maryland, the US.
Headquarters
United States of America
Address
9704 Medical Center Drive, Rockville, Maryland, 20850
Website
www.macrogenics.com
Telephone
1 301 2515172
No of Employees
293
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MGNX (NASD)
Revenue (2024)
$149.5M
-0.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-11.4%
(2024 vs 2023)
Market Cap*
$293.7M
Net Profit Margin (2024)
XYZ
-11.8%
(2024 vs 2023)
* As of and is in US$
MacroGenics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| - |
| Pipeline |
| Lorigerlimab: An investigational, bispecific DART molecule that targets PD-1 and CTLA-4 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Divestiture | In May, the company entered into an agreement to sell GMP manufacturing operations to bora pharmaceuticals. |
| 2026 | Contracts/Agreements | In May, the company entered into a partnership with Sagard Healthcare for a capped royalty interest on future global net sales of ZYNYZ. |
| 2025 | Contracts/Agreements | In June, the company entered into a royalty purchase agreement for ZYNYZ with Sagard Healthcare Partners. |
Competitor Comparison
| Key Parameters | MacroGenics Inc | Merck & Co Inc | Pfizer Inc | AbbVie Inc | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United Kingdom |
| City | Rockville | Rahway | New York City | North Chicago | Cambridge |
| State/Province | Maryland | New Jersey | New York | Illinois | Cambridgeshire |
| No. of Employees | 293 | 75,000 | 75,000 | 57,000 | 96,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William Heiden | Chairman | Executive Board | 2022 | 66 |
| Eric Risser | Chief Executive Officer; Director; President - President | Executive Board | 2025 | 53 |
| James Karrels | Chief Financial Officer; Senior Vice President | Senior Management | 2008 | 59 |
| Ezio Bonvini, M.D. | Chief Scientific Officer; Senior Vice President - Research | Senior Management | 2020 | 72 |
| Jeffrey Peters | Corporate Compliance Officer; General Counsel; Secretary; Senior Vice President | Senior Management | 2015 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer